Pierre Chelle

Publication Activity (10 Years)

Years Active: 2019-2024
Publications (10 Years): 13

Top Topics

Replacement Therapy

Palliative Care

Ejection Fraction

Top Venues

Haemophilia : the official journal of the World Federation of Hemophilia

Journal of thrombosis and haemostasis : JTH

Journal of pharmacokinetics and pharmacodynamics

This page only lists publications with an associated author ORCID identifier.

Publications

Pierre Chelle, Dagmar Hajducek, Karen Thibaudeau, Nicholas Hobson, Alfonso Iorio, Amy D Shapiro, Andrea N Edginton
Development of a Plasminogen Population PK model supporting prophylactic replacement therapy for Plasminogen deficient patients within the WAPPS-Hemo platform. Haemophilia : the official journal of the World Federation of Hemophilia (2024)
Pierre Chelle, Dagmar Hajducek, Karen Thibaudeau, Nicholas Hobson, Alfonso Iorio, Amy D Shapiro, Andrea N Edginton
Development of a Plasminogen Population PK model supporting prophylactic replacement therapy for Plasminogen deficient patients within the WAPPS-Hemo platform. Haemophilia : the official journal of the World Federation of Hemophilia 30 (4) (2024)
Davide Matino, Federico Germini, Anthony K C Chan, Kay Decker, Emma Iserman, Pierre Chelle, Andrea N Edginton, Olayide Oladoyinbo, Elisabetta Trinari, Arun Keepanasseril, Alfonso Iorio
Canadian clinical experience on switching from standard half-life recombinant factor VIII (rFVIII), octocog alfa, to extended half-life rFVIII, damoctocog alfa pegol, in persons with haemophilia A ≥ 12 years followed in a Comprehensive Hemophilia Care Program in Canada. Haemophilia : the official journal of the World Federation of Hemophilia (2024)
Davide Matino, Federico Germini, Anthony K C Chan, Kay Decker, Emma Iserman, Pierre Chelle, Andrea N Edginton, Olayide Oladoyinbo, Elisabetta Trinari, Arun Keepanasseril, Alfonso Iorio
Canadian clinical experience on switching from standard half-life recombinant factor VIII (rFVIII), octocog alfa, to extended half-life rFVIII, damoctocog alfa pegol, in persons with haemophilia A ≥ 12 years followed in a Comprehensive Hemophilia Care Program in Canada. Haemophilia : the official journal of the World Federation of Hemophilia 30 (2) (2024)
Dagmar M Hajducek, Pierre Chelle, Alfonso Iorio, Emma Iserman, Andrea N Edginton
Estimated prophylactic dose required to achieve 3% trough as a function of age and concentrate class in multi-country severe WAPPS-Hemo haemophilia patients. Haemophilia : the official journal of the World Federation of Hemophilia 30 (4) (2024)
Dagmar M Hajducek, Pierre Chelle, Alfonso Iorio, Emma Iserman, Andrea N Edginton
Estimated prophylactic dose required to achieve 3% trough as a function of age and concentrate class in multi-country severe WAPPS-Hemo haemophilia patients. Haemophilia : the official journal of the World Federation of Hemophilia (2024)
Pierre Chelle, Dagmar Hajducek, Karen Thibaudeau, Nicholas Hobson, Alfonso Iorio, Amy D Shapiro, Andrea N Edginton
Development of a Plasminogen Population PK model supporting prophylactic replacement therapy for Plasminogen deficient patients within the WAPPS-Hemo platform. Haemophilia : the official journal of the World Federation of Hemophilia 30 (4) (2024)
Davide Matino, Federico Germini, Anthony K C Chan, Kay Decker, Emma Iserman, Pierre Chelle, Andrea N Edginton, Olayide Oladoyinbo, Elisabetta Trinari, Arun Keepanasseril, Alfonso Iorio
Canadian clinical experience on switching from standard half-life recombinant factor VIII (rFVIII), octocog alfa, to extended half-life rFVIII, damoctocog alfa pegol, in persons with haemophilia A ≥ 12 years followed in a Comprehensive Hemophilia Care Program in Canada. Haemophilia : the official journal of the World Federation of Hemophilia 30 (2) (2024)
Davide Matino, Federico Germini, Anthony K C Chan, Kay Decker, Emma Iserman, Pierre Chelle, Andrea N Edginton, Olayide Oladoyinbo, Elisabetta Trinari, Arun Keepanasseril, Alfonso Iorio
Canadian clinical experience on switching from standard half-life recombinant factor VIII (rFVIII), octocog alfa, to extended half-life rFVIII, damoctocog alfa pegol, in persons with haemophilia A ≥ 12 years followed in a Comprehensive Hemophilia Care Program in Canada. Haemophilia : the official journal of the World Federation of Hemophilia (2024)
Pierre Chelle, Alfonso Iorio, Andrea N Edginton
A personalized limited sampling approach to better estimate terminal half-life of FVIII concentrates. Journal of thrombosis and haemostasis : JTH 20 (9) (2022)
Raphaël Crépin, Claire Morin, Aurélie Montmartin, Brigitte Tardy, Pierre Chelle
Use of population PK/PD approach to model the thrombin generation assay: assessment in haemophilia A plasma samples spiked by a TFPI antibody. Journal of pharmacokinetics and pharmacodynamics 48 (4) (2021)
Olav Versloot, Emma Iserman, Pierre Chelle, Federico Germini, Andrea N Edginton, Roger E G Schutgens, Alfonso Iorio, Kathelijn Fischer, null null
Terminal half-life of FVIII and FIX according to age, blood group and concentrate type: Data from the WAPPS database. Journal of thrombosis and haemostasis : JTH 19 (8) (2021)
Mohamed Aborig, Paul R V Malik, Shruti Nambiar, Pierre Chelle, Johnson Darko, Anthony J Mutsaers, Andrea N Edginton, Andre Fleck, Ernest Osei, Shawn D Wettig
Biodistribution and Physiologically-Based Pharmacokinetic Modeling of Gold Nanoparticles in Mice with Interspecies Extrapolation. Pharmaceutics 11 (4) (2019)